Pharmaceutical company Avenacy has launched Propofol injectable emulsion, USP, in the U.S. to be used for intravenous general anesthetic and sedation.
The drug has been approved by the FDA as a generic equivalent to general anesthetic Diprivan, according to an April 7 press release.
It is approved for use for induction of general anesthesia in patients over age 3, maintain anesthesia for patients over 2 months old, maintain monitored anesthesia care, sedate patients in combination with regional anesthesia and for intubation of mechanically ventilated patients.
This is Avenacy’s 21st product launch since October 2023.
